Quick Answer: Tirzepatide causes delayed gastric emptying by activating GLP-1 receptors, which slows food transit from stomach to intestine, improving glucose control and satiety but causing gastrointestinal side effects
HSPA9, heat shock protein family A member 9
Mounjaro (tirzepatide) is a prescription medicine licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for chronic weight management in adults with obesity or overweight with weight-related comorbidities
Humans express two urea transporter genes, SLC14A1 and SLC14A2, that encode transporters identified as UT-B and UT-A, respectively
Some people may combine them to support overall benefits like improved body composition, better recovery, and increased energy
No roundups, no filler